Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 536

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Open access
Sanchez, Gina A. Montealegre, Reinhardt, Adam, Ramsey, Suzanne, Wittkowski, Helmut, Hashkes, Philip J., Berkun, Yackov, Schalm, Susanne, Murias, Sara, Dare, Jason A., Brown, Diane, Stone, Deborah L., Gao, Ling, Klausmeier, Thomas, Foell, Dirk, de Jesus, Adriana A., Chapelle, Dawn C., Kim, Hanna, Dill, Samantha, Colbert, Robert A., Failla, Laura, Kost, Bahar, O’Brien, Michelle, Reynolds, James C., Folio, Les R., Calvo, Katherine R., Paul, Scott M., Weir, Nargues, Brofferio, Alessandra, Soldatos, Ariane, Biancotto, Angelique, Cowen, Edward W., Digiovanna, John J., Gadina, Massimo, Lipton, Andrew J., Hadigan, Colleen, Holland, Steven M., Fontana, Joseph, Alawad, Ahmad S., Brown, Rebecca J., Rother, Kristina I., Heller, Theo, Brooks, Kristina M., Kumar, Parag, Brooks, Stephen R., Waldman, Meryl, Singh, Harsharan K., Nickeleit, Volker, Silk, Maria, Prakash, Apurva, Janes, Jonathan M., Ozen, Seza, Wakim, Paul G., Brogan, Paul A., Macias, William L., Goldbach-Mansky, Raphaela·2018·Journal of Clinical Investigation

Abstract

BACKGROUND: Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to ameliorate disease. METHODS: Between October 2011 and February 2017, 10 patients with CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 patients with SAVI (stimulator of IFN genes-associated [STING-associated] vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an expanded access program. The patients underwent dose escalation, and the benefit was assessed by reductions in daily disease symptoms and corticosteroid requirement. Quality of life, organ inflammation, changes in IFN-induced biomarkers, and safety were longitudinally assessed. RESULTS: Eighteen patients were treated for a mean duration of 3.0 years (1.5-4.9 years). The median daily symptom score decreased from 1.3 (interquartile range [IQR], 0.93-1.78) to 0.25 (IQR, 0.1-0.63) (P < 0.0001). In 14 patients receiving corticosteroids at baseline, daily prednisone doses decreased from 0.44 mg/kg/day (IQR, 0.31-1.09) to 0.11 mg/kg/day (IQR, 0.02-0.24) (P < 0.01), and 5 of 10 patients with CANDLE achieved lasting clinical remission. The patients' quality of life and height and bone mineral density Z-scores significantly improved, and their IFN biomarkers decreased. Three patients, two of whom had genetically undefined conditions, discontinued treatment because of lack of efficacy, and one CANDLE patient discontinued treatment because of BK viremia and azotemia. The most common adverse events were upper respiratory infections, gastroenteritis, and BK viruria and viremia. CONCLUSION: Upon baricitinib treatment, clinical manifestations and inflammatory and IFN biomarkers improved in patients with the monogenic interferonopathies CANDLE, SAVI, and other interferonopathies. Monitoring safety and efficacy is important in benefit-risk assessment. TRIAL REGISTRATION: ClinicalTrials.gov NCT01724580 and NCT02974595. FUNDING: This research was supported by the Intramural Research Program of the NIH, NIAID, and NIAMS. Baricitinib was provided by Eli Lilly and Company, which is the sponsor of the expanded access program for this drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci98814

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 536

Metadata

Authors
Sanchez, G. A. M., Reinhardt, A., Ramsey, S., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murias, S., Dare, J. A., Brown, D., Stone, D. L., Gao, L., Klausmeier, T., Foell, D., de Jesus, A. A., Chapelle, D. C., Kim, H., Dill, S., Colbert, R. A., Failla, L., Kost, B., O’Brien, M., Reynolds, J. C., Folio, L. R., Calvo, K. R., Paul, S. M., Weir, N., Brofferio, A., Soldatos, A., Biancotto, A., Cowen, E. W., Digiovanna, J. J., Gadina, M., Lipton, A. J., Hadigan, C., Holland, S. M., Fontana, J., Alawad, A. S., Brown, R. J., Rother, K. I., Heller, T., Brooks, K. M., Kumar, P., Brooks, S. R., Waldman, M., Singh, H. K., Nickeleit, V., Silk, M., Prakash, A., Janes, J. M., Ozen, S., Wakim, P. G., Brogan, P. A., Macias, W. L., & Goldbach-Mansky, R.
Venue
Journal of Clinical Investigation
Published
2018-06-11
Volume
128
Issue
7
Pages
3041-3052
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2796581040
Cited by
536
References
38
FWCI
23.37
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. https://app.cochat.ai/papers/10.1172/jci98814
The paper
Sanchez, G. A. M., Reinhardt, A., Ramsey, S., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murias, S., Dare, J. A., Brown, D., Stone, D. L., Gao, L., Klausmeier, T., Foell, D., de Jesus, A. A., Chapelle, D. C., Kim, H., Dill, S., Colbert, R. A., . . . Goldbach-Mansky, R. (2018). JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. Journal of Clinical Investigation. https://doi.org/10.1172/jci98814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.